G

PriceGrace Therapeutics

GRCE

Grace Therapeutics Inc is a late-stage specialty pharma company with drug delivery technologies and drug candidates addressing rare and orphan diseases. The company's lead drug candidate, GTx-104, is a novel injectable formulation of nimodipine for the treatment of a rare disease, aneurysmal subarachnoid hemorrhage.

Historical stock price chart and annual return over the past years

-87%

5 years

% Total

GRCE
-34%

5 years

Annual Return

GRCE